Differential effects of acute and sustained cyclosporine and tacrolimus on sympathetic nerve activity

Journal of Hypertension

Volumn 28, Issue 9, 2010, Pages 1928-1934

  Klein, Inge Hht ^a,b   Abrahams, Alferso C ^a   Van Ede, Thomas ^a   Oey, P Liam ^a   Ligtenberg, Gerry ^a   Blankestijn, Peter J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SLINGELAND HOSPITAL   (Netherlands)

Author keywords

blood pressure; calcineurin inhibitor; cyclosporine; healthy volunteers; hypertension; sympathetic nerve activity; sympathetic nervous system; tacrolimus

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; TACROLIMUS;

ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ASSESSMENT; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SYMPATHETIC NERVE; SYMPATHETIC TONE; TREATMENT DURATION; WEIGHT GAIN;

EID: 77955849403     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833c20eb     Document Type: Article

References (42)

1. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002; 2:807-818.
2. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporine as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331:810.
3. McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006; 6:1578-1585.
4. Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001; 12:368-373.
5. Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003; 14:1880-1888.
6. Keogh A. Calcineurin inhibitors in heart transplantation. J Heart Lung Transplant 2004; 23:S202-S206.
7. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med 1994; 331:1110-1115.
8. Ghafari A, Makhdoomi K, Ahmadpour P, Afshari AT, Fallah MM, Rad PS. Low-dose versus high-dose cyclosporine induction protocols in renal transplantation. Transplant Proc 2007; 39:1219-1222.
9. Beckebaum S, Klein CG, Sotiropoulos GC, Saner FH, Gerken G, Paul A, Cicinnati VR. Combined mycophenolate mofetil and minimal dose calcineurin inhibitor therapy in liver transplant patients: clinical results of a prospective randomized study. Transplant Proc 2009; 41:2567-2569.
10. Scherrer U, Vissing SF, Morgan BJ, Rollins JA, Tindall RS, Ring S, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990; 323:693-699.
11. Hausberg M, Lang D, Levers A, Suwelack B, Kisters K, Tokmak F, et al. Sympathetic nerve activity in renal transplant patients before and after withdrawal of cyclosporine. J Hypertens 2006; 24:957-964.
12. Kaye D, Thompson J, Jennings G, Esler M. Cyclosporine therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation. Circulation 1993; 88:1101-1109.
13. Rundqvist B, Elam M, Eisenhofer G, Friberg P. Normalization of total body and regional sympathetic hyperactivity in heart failure after heart transplantation. J Heart Lung Transplant 1996; 15:516-526.
14. Lyson T, Ermel LD, Belshaw PJ, Alberg DG, Schreiber SL, Victor RG. Cyclosporine-and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling. Circ Res 1993; 73:596-602.
15. Textor SC, Taler SJ, Canzanello VJ, Schwartz L, Augustine JE. Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl 2000; 6:521-530.
16. Jardine AG. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Transpl Int 2005; 18:379-384.
17. Hagbarth KE, Vallbo AB. Pulse and respiratory grouping of sympathetic impulses in human muscle-nerves. Acta Physiol Scand 1968; 74:96-108.
18. Ligtenberg G, Blankestijn PJ, Oey PL, Wieneke GH, van Huff el en AC, Koomans HA. Cold stress provokes sympathoinhibitory presyncope in healthy subjects and hemodialysis patients with low cardiac output. Circulation 1997; 95:2271-2276.
19. Boer P, Sleumer JH, Spriensma M. Confirmation of the optimal pH for measuring renin activity in plasma. Clin Chem 1985; 31:149-150.
20. Carruthers SG, Freeman DJ, Koegler JC, Howson W, Keown PA, Laupacis A, Stiller CR. Simplified liquid-chromotographic analysis for cyclosporin A, and comparison with radioimmunoassay. Clin Chem 1983; 29:180-183.
21. Sturrock ND, Lang CC, Struthers AD. Cyclosporin-induced hypertension precedes renal dysfunction and sodium retention in man. J Hypertens 1993; 11:1209-1216.
22. Sturrock ND, Lang CC, MacFarlane LJ, Dockrell ME, Ryan M, Webb DJ, Struthers AD. Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyclosporin therapy in males. J Hypertens 1995; 13:667-673.
23. Hansen JM, Fogh-Andersen N, Christensen NJ, Strandgaard S. Cyclosporine-induced hypertension and decline in renal function in healthy volunteers. J Hypertens 1997; 15:319-326.
24. Klein IH, Abrahams A, van Ede T, Hene RJ, Koomans HA, Ligtenberg G. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73:732-736.
25. Textor SC, Burnett JC Jr, Romero JC, Canzanello VJ, Taler SJ, Wiesner R, et al. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int 1995; 47:1426-1433.
26. Canzanello VJ, Textor SC, Taler SJ, Wilson DJ, Schwartz L, Wiesner RH, et al. Renal sodium handling with cyclosporin A and FK506 after orthotopic liver transplantation. J Am Soc Nephrol 1995; 5:1910-1917.
27. Esteva-Font C, Ars E, Guillen-Gomez E, Campistol JM, Sanz L, Jimenez W, et al. Ciclosporin-induced hypertension is associated with increased sodium transporter of the loop of Henle (NKCC2). Nephrol Dial Transplant 2007; 22:2810-2816.
28. Bantle JP, Boudreau RJ, Ferris TF. Suppression of plasma renin activity by cyclosporine. Am J Med 1987; 83:59-64.
29. Stein CM, He H, Pincus T, Wood AJ. Cyclosporine impairs vasodilation without increased sympathetic activity in humans. Hypertension 1995; 26:705-710.
30. Carvalho MJ, van den Meiracker AH, Boomsma F, Freitas J, Man in 't Veld AJ, Costa O, de Freitas AF. Role of sympathetic nervous system in cyclosporine-induced rise in blood pressure. Hypertension 1999; 34:102-106.
31. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106:1974-1979.
32. Araujo GC, Lopes OU, Campos RR. Importance of glycinergic and glutamatergic synapses within the rostral ventrolateral medulla for blood pressure regulation in conscious rats. Hypertension 1999; 34:752-755.
33. Sakima A, Yamazato M, Sesoko S, Muratani H, Fukiyama K. Cardiovascular and sympathetic effects of L-glutamate and glycine injected into the rostral ventrolateral medulla of conscious rats. Hypertens Res 2000; 23:633-641.
34. Victor RG, Thomas GD, Marban E, O'Rourke B. Presynaptic modulation of cortical synaptic activity by calcineurin. Proc Natl Acad Sci\USA 1995; 92:6269-6273.
35. Zhang W, Victor RG. Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension. Am J Hypertens 2000; 13:999-1004.
36. Zhang W, Li JL, Hosaka M, Janz R, Shelton JM, Albright GM, et al. Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings. Proc Natl Acad Sci\USA 2000; 97:9765-9770.
37. Faber JE, Brody MJ. Afferent renal nerve-dependent hypertension following acute renal artery stenosis in the conscious rat. Circ Res 1985; 57:676-688.
38. Nankivell BJ, Chapman JR, Bonovas G, Gruenewald SM. Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation 2004; 77:1457-1459.
39. Dello Strologo L, Pontesilli C, Montini G, Ginevri F, Ardissino G, Campagnano P, et al. Renal hemodynamic effect of tacrolimus in renal transplanted children. Pediatr Nephrol 2001; 16:773-776.
40. Gardiner SM, March JE, Kemp PA, Fallgren B, Bennett T. Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats. Br J Pharmacol 2004; 141:634-643.
41. Grassi G, Bolla G, Seravalle G, Turri C, Lanfranchi A, Mancia G. Comparison between reproducibility and sensitivity of muscle sympathetic nerve traffic and plasma noradrenaline in man. Clin Sci (Lond) 1997; 92:285-289.
42. Fagius J, Wallin BG. Long-term variability and reproducibility of resting human muscle nerve sympathetic activity at rest, as reassessed after a decade. Clin Auton Res 1993; 3:201-205.